Q-omics provides the consensus-scored ZMAT3 profile across patient tissues and cancer cell-line models. ZMAT3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZMAT3 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZMAT3 RNA expression shows 18,646 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where ZMAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMAT3 survival associations across molecular data types. ZMAT3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMAT3 RNA expression–survival associations across cancer types. High ZMAT3 expression shows unfavorable associations in BLCA, ESCA and BRCA, but favorable associations in KIRC, THCA and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for ZMAT3 RNA expression.
This table summarizes ZMAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZMAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMAT3 shows lower tumor expression in KICH and higher tumor expression in THCA, KIRP, LIHC, HNSC and CHOL. The THCA box plot shows higher ZMAT3 RNA expression in tumor versus normal tissue (log2 FC = +1.546, t-test p < 0.001).
This table shows molecular features associated with ZMAT3 in patient tissues and cancer cell lines. In patient samples, ZMAT3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMAT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
